Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis

Table 2 Intervention characteristics and outcome measures of the trials included in this meta-analysis

Ref.	Intervention	Patients	Follow-up (mo)	Sorafenib dose	Sorafenib duration (mo)	OS (mo)		TTP (mo)		PFS (mo)		DCR (%)
						Median	HR (95%CI)	Median	HR (95%CI)	Median	HR (95%CI)
Koch et al[19], 2021	TACE was usually initiated before sorafenib	54	NA	NA	NA	16.5	0.34 (0.23-0.53)	7.0	NA	NA	NA	28/53 (53)
	Sorafenib alone	82	NA		NA	8.4		4.1		NA		17/74 (23)
Park et al[20], 2019	Sorafenib initiated within 3 d of randomization, first TACE initiated between 7 and 21 d after randomization	170	14 (4-27)	200-400 mg twice daily, then 400 mg twice daily	5.5 (0.1-41.6)	12.8	0.91 (0.69-1.21)	5.3	0.67 (0.53-0.85)	5.2	0.73 (0.59-0.91)	103/170 (61)
	Sorafenib initiated within 3 d of randomization	169	19 (2-27)		4.3 (0.2-48.4)	10.8		3.5		3.6		80/169 (47)
Kok et al[23], 2019	Sorafenib prior to TACE	426	7.4 (4.7-11.5)	NA	4.7 (4.2-5.3)	12.5	0.74 (0.63-0.88)	4.7	0.76 (0.65-0.89)	NA	NA	NA
	Sorafenib alone	1686	4.4 (2.3-8.4)		2.8 (2.6-3.0)	6.7		2.8		NA
Wu et al[21], 2017	Sorafenib prior to TACE	56	NA	400 mg twice daily	NA	22	0.50 (0.28-0.89)	NA	NA	8	0.46 (0.27-0.78)	27/48 (56)1
	Sorafenib alone	48	NA		NA	18		NA		6		23/40 (58)
Zhang et al[22], 2015	Sorafenib started 1-3 d after TACE	45	7.3 (2-18)	NA	5.6 (1-18)	7	1.17 (0.52-1.81)	3	NA	NA	NA	24/43 (60)
	Sorafenib alone	44			5.4 (1-17)	6		3		NA		18/44 (51)

¹DCR was measured at the 6^th month.

Data are n (%) for categories, and median for continuous data. OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression; DCR: Disease control rate; TACE: Transarterial chemoembolization; HR: Hazard ratio; 95%CI: 95% confidence interval; NA: Not available.